Capital Health System, Bristol-Myers Squibb to spread awareness about chronic diseases, prescription drugs
PRINCETON, N.J. Bristol-Myers Squibb and Capital Health System have announced that they will co-host a health fair Tuesday, Oct.14, to highlight the importance of managing chronic diseases and disseminate information about assistance programs created to help low-income patients pay for prescription drugs.
The fair is scheduled to start at noon and run until 3 p.m. at the Capital Health System Family Health Center in Trenton. Free wellness screenings will be given and actor Joey Pantoliano will make an appearance and speak about diagnosing and treating depression.
Pantoliano will speak on behalf of the Partnership for Prescription Assistance, a nationwide network of pharmaceutical makers working to provide assistance to low-income individuals to pay for their medications for chronic illnesses.
Capital Health System also will provide free high blood pressure, diabetes, dyslipidemia and HIV/AIDS screenings, free vision tests, perform height and weight screenings and distribute information about breast, colorectal and prostate cancers.
Other health-related information provided by Capital and Bristol-Myers Squibb at the fair will cover body composition screenings for newborns, breast-feeding information for new mothers as well as bicycle safety training and demos on and car seat installations for small children.
Shopko donates school supplies to Green Bay area elementary school
GREEN BAY, Wis. An elementary school in Green Bay received a variety of school supplies from a locally headquartered retail chain.
Shopko announced Oct. 2 that it had donated the supplies to Sunrise River Elementary, which serves students in second through fifth grade. The supplies included basic items from the school’s required supply list.
Shopko operates stores throughout the Midwest and West.
ARCA Biopharma makes unprecedented payment to Aeolus following FDA approval of bucindolol
NEW YORK Aeolus Pharmaceuticals announced Friday that it had received a $175,000 milestone payment from ARCA Biopharma following the Food and Drug Administration’s acceptance of an approval application for a cardiovascular drug.
Aeolus said the drug, bucindolol, could be the first genetically targeted cardiovascular therapy. CPEC, a company owned jointly by Aeolus and Indevus Pharmaceuticals, licensed all rights to bucindolol to ARCA.
“ARCA’s success in demonstrating the potential benefits of bucindolol in treating heart failure in patients is encouraging,” Aeolus president and chief executive officer John McManus said in a statement. “We look forward to an expeditious review and hope for a positive outcome.”